FindTrial
Sign In

Exercise intervention on severity of chemotherapy induced peripheral neuropathy in cancer patients

Efficacy of the exercise intervention on severity of chemotherapy induced peripheral neuropathy among cancer patients - A randomized clinical trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/10/046907
Enrollment
158
Registered
2022-10-31
Start date
Unknown
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site Health Condition 2: C569- Malignant neoplasm of unspecifiedovary

Interventions

Intervention1: Sensory - motor exercise: Participants in the Intervention group will receive exercise treatment four times per week for 35 minutes. During an introductory one – on – one training sessi

Sponsors

Manipal Academy of Higher Education
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Diagnosed with histologically verified, non-metastatic cancer for the first time. 2.Planned for administration of Paclitaxel regimen.

Exclusion criteria

Exclusion criteria: 1.All diagnosed cases of peripheral neuropathy. 2.Participants with metastases to the central or peripheral nervous systems 3.Primary brain tumor. 4.Nerve conduction examinations, the absences of Sensory nerve action potential (SNAP) / Compound muscle action potential (CMAP) conduction were examined on the baseline study. 5.Severe Ischemic heart disease (Ejection fraction 6.Acute exacerbation of chronic obstructive pulmonary disease or Asthma 7.Severe congestive cardiac failure or acute myocardial infarction less than 3 months. 8.A history of moderate to severe alcohol use disorder according to DSM – 5 criteria

Design outcomes

Primary

MeasureTime frame
Nerve Conduction Studies Patient Neurotoxicity Questionnaire National Cancer Institute Common Terminology Criteria for Adverse Events: Neuropathy and Pain – for Chemotherapy Induced Peripheral Neuropathy grading Bio – Marker Neuro – filament light chain by using ELISA kit For Balance: Fullerton Advanced Balance Scale (FAB) EORTC QLQ-C30 (version 3) Timepoint: Baseline values: Before starting the paclitaxel. Second values: At the last cycle of paclitaxel. Follow up: After three months completion of last cycle of paclitaxel.—

Secondary

MeasureTime frame
not applicableTimepoint: not applicable—

Countries

India

Contacts

Public ContactMangaiyarkarasi S

Kasturba Medical College and Hospital

udupa.karthik@manipal.edu9845317153

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026